[BMY] Bristol-Myers Squibb Company

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 128.21 B

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 59.6 Change: 0.82 (1.4%)
Ext. hours: Change: 0 (0%)

chart BMY

Refresh chart

Strongest Trends Summary For BMY

BMY is in the long-term down -31% below S&P in 2 years and up 219% in 22 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding1.67 B EPS2.51 EPS Growth - 4 Quarters-704.03% EPS Growth - Q/Q-233.04%
EPS Growth - Y/Y-255.12% Sales Growth - 4 Quarters 6.17% Sales Growth - Q/Q3.02% P/E21.7
P/E To EPS Growth0.28 P/S7.83 P/BV8.48 Price/Cash Per Share23.41
Price/Free Cash Flow48.9 ROA5.6% ROE11.84% ROI7.56%
Current Ratio1.76 Quick Ratio1.58 Long Term Debt/Equity1.18 Debt Ratio0.49
Gross Margin76.6% Operating Margin14.94% Net Profit Margin10.93% Dividend Payout Ratio-136.15%
Dividend Yield-1.9%
Fundamental Data
Cash From Financing Activities-1.57 B Cash From Investing Activities-526 M Cash From Operating Activities697 M Gross Profit3.18 B
Net Profit-130 M Operating Profit45 M Total Assets31.95 B Total Current Assets13.06 B
Total Current Liabilities7.44 B Total Debt7.37 B Total Liabilities16.83 B Total Revenue4.16 B
Technical Data
High 52 week62.66 Low 52 week42.77 Last close47.32 Last change0.06%
RSI79.2 Average true range1.11 Beta0.67 Volume5.04 M
Simple moving average 20 days5.46% Simple moving average 50 days3.65% Simple moving average 200 days-1.71%
Performance Data
Performance Week2.89% Performance Month6.27% Performance Quart1.55% Performance Half-4.95%
Performance Year-20.85% Performance Year-to-date-8.14% Volatility daily1.49% Volatility weekly3.34%
Volatility monthly6.85% Volatility yearly23.72% Relative Volume180.93% Average Volume13.49 M
New High New Low

News

2019-09-16 10:43:02 | AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

2019-09-13 10:30:02 | Celgene's CELG Leukemia Candidate Meets Endpoints in Study

2019-09-13 09:36:01 | Renal Cell Carcinoma Space in Focus: Some Key Developments

2019-09-13 04:47:08 | Roche Reports Positive Data on Tecentriq & NMOSD Drug Revised

2019-09-12 19:25:34 | Seth Klarman's Favorite Health Care Stocks

2019-09-12 17:46:53 | Gilead Tops List of Most Innovative Drug Companies

2019-09-12 13:36:51 | 2 Large-Cap Companies Declare Dividends

2019-09-12 10:02:02 | Horizon HZNP Up 36.7% YTD: Pipeline Development in Focus

2019-09-12 09:20:01 | Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb

2019-09-12 09:09:01 | Roche RHHBY Reports Positive Data on Tecentriq & MS Drug

2019-09-12 07:59:11 | Top Ranked Income Stocks to Buy for September 12th

2019-09-12 07:43:11 | Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks

2019-09-12 06:59:00 | Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019

2019-09-11 17:45:09 | Bristol-Myers Squibb BMY Outpaces Stock Market Gains: What You Should Know

2019-09-11 17:39:00 | Bristol-Myers Squibb Board Announces Election of Three New Directors

2019-09-11 16:16:00 | Bristol?Myers Squibb Announces Dividend

2019-09-11 12:05:04 | Could the Trade War be Bullish for Stocks?

2019-09-11 11:40:03 | AVEO Surges on Favorable Updated OS Results on RCC Drug

2019-09-11 11:13:03 | Bristol-Myers' BMY Opdivo Shows Long-Term Survival Benefit

2019-09-11 09:32:01 | 4 Big Drugmakers Boasting Impressive Oncology Pipelines

2019-09-10 13:38:00 | 7 Cheap Stocks to Buy in a Pricey Market

2019-09-10 11:18:19 | Aveo CEO says new data eases concerns about troubled kidney cancer drug

2019-09-10 05:30:00 | Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo nivolumab in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients

2019-09-09 11:33:03 | The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers

2019-09-09 09:15:01 | Why Bristol-Myers Squibb BMY is a Great Dividend Stock Right Now

2019-09-09 07:25:11 | Top Ranked Income Stocks to Buy for September 9th

2019-09-08 09:00:00 | Better Buy: Amgen vs. Celgene

2019-09-07 12:30:00 | Is Bristol-Myers Squibb a Buy?

2019-09-06 15:06:00 | Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy

2019-09-06 11:36:03 | Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs

2019-09-06 11:29:03 | Bristol-Myers' BMY Opdivo Falls Flat in Brain Tumor Study

2019-09-05 16:51:07 | 3 Special Situations Gurus Are Buying

2019-09-05 10:24:02 | Infinity Initiates 2 Studies for Lead Candidate IPI-549

2019-09-05 08:58:12 | The Zacks Analyst Blog Highlights: Allegiant, Bristol-Myers, NewMarket, North American Construction and TiVo

2019-09-05 08:12:42 | The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

2019-09-05 07:24:00 | Bristol-Myers cancer drug Opdivo fails to meet a primary endpoint in phase 3 trial

2019-09-05 07:09:20 | Bristol-Myers' Opdivo fails to meet goal of brain tumor study

2019-09-05 07:01:25 | Novartis signs $840M pact with IFM Due amid fallout from AveXis deal

2019-09-05 05:10:00 | Bristol-Myers Stock Slips After Brain-Cancer-Drug Disappointment

2019-09-04 15:14:00 | Here's Why Nektar Therapeutics Plummeted 38% in August

2019-09-04 09:39:01 | Roche Extends Offer to Acquire Spark Therapeutics Yet Again

2019-09-04 09:22:01 | 5 Strong Buy Ultra-Safe Stocks for an Uncertain September

2019-09-04 09:19:01 | The Zacks Analyst Blog Highlights: TransDigm, Keysight, Bristol-Myers Squibb, NRG and Arconic

2019-09-04 07:00:00 |  More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research

2019-09-03 17:46:09 | Top-Performing Biotech ETFs YTD

2019-09-03 09:21:01 | The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

2019-09-03 07:02:11 | 5 Cancer-Fighting Stocks to Add to Your Portfolio

2019-09-02 07:14:11 | 5 Top S&P 500 Stocks Soaring Despite Worst August Since 2015

2019-08-30 17:45:09 | Bristol-Myers Squibb BMY Stock Sinks As Market Gains: What You Should Know

2019-08-30 11:33:03 | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Alamos Gold, Americold Realty Trust, TransDigm and frontdoor